XENE — Xenon Pharmaceuticals Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1582313 ·
British Columbia, Canada
Last close
$60.56
Market Cap
$5.86B
52W High
$72.66
52W Low
$50.91
ADV30
710,764
Next earnings
2026-11-02
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -112,328,000 | -102,302,000 | 1,386,810,000 | 545,867,000 | 48,991,000 |
| Dec 2025 | 0 | — | -109,767,000 | -105,261,000 | 633,163,000 | 199,163,000 | 51,403,000 |
| Sep 2025 | 0 | — | -96,336,000 | -90,896,000 | 607,836,000 | 104,514,000 | 48,325,000 |
| Jun 2025 | 0 | — | -94,229,000 | -84,706,000 | 674,281,000 | 135,381,000 | 40,303,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-306,363,000
Investing CF
$-223,794,000
Financing CF
$958,975,000
CapEx
$-889,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.70
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,347,682,000
Inventory
—
Receivables
$1,165,000
ST Investments
$548,880,000
EBIT TTM
$-412,660,000
Pretax Income TTM
$-385,147,000
Interest Exp TTM
—
Analysts
19
Yahoo Snapshot (yfinance, live)
Total Revenue
$0
EBITDA
$-439,188,992
Free Cash Flow
$-203,547,248
Enterprise Value
$4,940,388,352
Total Cash
$930,686,016
Total Debt
$6,418,000
Shares Out
96,840,432
Trailing EPS
$-4.72
Book Value
$12.84
ROE
-43.6%
ROA
-28.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 7,500,000 | -373,070,000 | -345,910,000 | 633,163,000 | 51,403,000 | — | -279,118,000 |
| Dec 2024 | 0 | -279,298,000 | -234,330,000 | 798,139,000 | 43,236,000 | — | -181,389,000 |
| Dec 2023 | 0 | -214,054,000 | -182,393,000 | 964,798,000 | 36,877,000 | — | -151,112,000 |
| Dec 2022 | 9,434,000 | -129,143,000 | -125,373,000 | 754,146,000 | 32,649,000 | — | -101,028,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-4.87
Max Pain — expiry 2026-10-16
max pain strike: $50.00 · spot: $60.56 · call oi: 9,910 · put oi: 188Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MIRM | Mirum Pharmaceuticals, Inc. | $5.90B | $96.72 | — |
| PTCT | PTC THERAPEUTICS, INC. | $5.93B | $71.06 | — |
| DNTH | Dianthus Therapeutics, Inc. /DE/ | $6.02B | $110.07 | — |
| TVTX | Travere Therapeutics, Inc. | $6.06B | $65.22 | — |
| ERAS | Erasca, Inc. | $6.16B | $17.60 | — |
News headlines (Yahoo Finance, 1h cache)
Xenon Pharmaceuticals (XENE) Q2 2026 Earnings Call Transcript
2026-08-13 21:58 · Yahoo
Major Depressive Disorder Market is Predicted to Grow During the Forecast Period (2026-2036) as Novel Antidepressants are Expected to Enter the Market | DelveInsight
2026-08-10 14:31 · Yahoo
Xenon Pharmaceuticals' Azetukalner NDA Filing Remains on Track After FDA Meeting, RBC Says
2026-08-07 18:02 · Yahoo
Xenon Pharmaceuticals Inc (XENE) (Q2 2026) Earnings Call Highlights: Advancing Azetukalner ...
2026-08-07 05:09 · Yahoo
Xenon Reports Q2 2026 Financial Results and Provides Business Update
2026-08-06 20:01 · Yahoo
Xenon to Report Q2 2026 Financial Results on August 6, 2026
2026-07-30 20:01 · Yahoo
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-02 20:01 · Yahoo
Assessing Xenon Pharmaceuticals (XENE) Valuation After Recent Share Price Pullback And Modest Undervaluation Estimate
2026-06-11 17:11 · Yahoo
JPMorgan Raises its Price Target on Xenon Pharmaceuticals (XENE)
2026-05-23 02:31 · Yahoo
What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing
2026-05-18 17:44 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.